Funding Update: Loan Facility Extension & Increase

Kazera Global plc (AIM: KZG), the AIM-quoted investment company is pleased to announce that it has agreed with Richard Jennings (the "Lender") to extend and increase the unsecured loan facility originally entered into in August 2024 (the "Loan Agreement"), as detailed in an RNS dated 9 August 2024 and subsequently varied on 28 October 2025.

Under the Loan Agreement (as previously varied), the loan was due for repayment on or before 30 April 2026 (the "Existing Loan"). The Company and the Lender have agreed, pursuant to a second variation agreement, to extend the repayment date to 1 December 2026 and to increase the total amount available to the Company by up to £500,000, in order to provide continued financial flexibility as the Company advances its operations (the "New Facility").

The total amount outstanding under the Existing Loan prior to the loan extension, was £187,880 ("Loan Balance").

The Company remains in discussions with Tracarta Limited, a separate lender to the Company, in respect of its loan facility, pursuant to which, £436,128 is due to mature on 30 April 2026.

Revised Terms

The principal revised terms of the Loan Agreement (as further varied) are as follows:

• Term: Extended from 30 April 2026 to 1 December 2026.
• Increase in Facility: The total facility available to the Company has been increased by up to £500,000 through the provision of an additional unsecured term loan facility under the Loan Agreement (as varied).
• Drawdown: The New Facility is expected to be drawn in tranches, including £50,000 on or around 1 May 2026 and £50,000 on or around 1 June 2026, with further drawdowns at such times and in such amounts as may be mutually agreed in writing between the parties, subject to the aggregate limit of £500,000.
• Lender Discretion: The Lender's obligation to advance any tranche beyond the initial drawdown is subject to the Lender being satisfied, in its sole discretion, as to the Company's capacity to repay amounts outstanding under the Loan Agreement.
• Interest and Fees: Fixed interest of £18,788 (being 10% of the Loan Balance), plus an amount equal to 10% of the additional amount drawn under the New Facility.
• Repayment: All amounts outstanding under the Loan Agreement, together with any amounts drawn under the New Facility and associated charges, will be repayable on 1 December 2026.

All other terms of the Loan Agreement remain unchanged.

The Board believes that the extension and increase of the facility from Richard Jennings provides the Company with additional financial flexibility as it continues to progress its operational priorities and engage constructively with its other lender, Tracarta Limited.

Further updates will be provided as appropriate.

Geoff Eyre, Non-Executive Chairman of Kazera, commented: "We are very pleased to have secured this additional funding support from our CEO and largest shareholder Richard Jennings, which provides the Company with increased liquidity as we advance the Company's clear strategic priorities as previously announced.

"Our near-term capital requirements are targeted and being spent almost exclusively at the asset level as evidence by the Board's salary deferrals, and this facility is an important step in supporting ongoing activity across the business.

"I would like to thank Richard for his continued unwavering support and firm message of confidence in Kazera's prospects to deliver shareholder value that this facility represents.

"We remain in discussions with Tracarta and are focused on reaching an appropriate outcome that supports the Company's ongoing development whilst delivering value for all shareholders."

Related Party Transaction

Richard Jennings is Interim Chief Executive Officer and a Director of the Company and is also a substantial shareholder. Accordingly, the extension of the Existing Loan and the New Facility constitute related party transactions pursuant to Rule 13 of the AIM Rules for Companies.

The independent Directors consider, having consulted with Strand Hanson Limited, the Company's nominated adviser, that the terms of the extension are fair and reasonable insofar as the Company's shareholders are concerned.